308 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
from the Phase 3 KarMMa-3 trial. Abecma is the first CAR T cell immunotherapy approved in the European Union for use in earlier lines of therapy … with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes. The approval covers all European Union member states
424B5
BMY
Bristol-Myers Squibb Co.
16 Feb 24
Prospectus supplement for primary offering
4:34pm
of domestic law by virtue of the European Union (Withdrawal) Act 2018 (“EUWA”); (ii) a customer within the meaning of the provisions of the Financial Services
424B2
hnt1yxs9u
13 Feb 24
Prospectus for primary offering
8:00am
8-K
EX-99.1
s4cv8
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
SC TO-T
EX-99
lrdj49
25 Jan 24
Third party tender offer statement
8:13am
424B5
nt2n xx3s
1 Nov 23
Prospectus supplement for primary offering
4:16pm
424B3
f261qee tgon3s3
30 Oct 23
Prospectus supplement
8:05am
8-K
EX-99.1
0c3o0t
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am